open access
The use of vemurafenib in BRAF-positive metastatic melanoma patients — selected cases reports
open access
Abstract
The incidence of cutaneous melanoma is constantly increasing. The primary treatment in early stage of disease remains surgery. New therapeutic strategies such as immunotherapy or selective BRAF inhibitors — vemurafenib and dabrafenib, have improved outcomes of treatment in the group of patients with stage IV melanoma. In Poland still only vemurafenib is available in routine clinical practice. In this article we present clinical experiences in treating of BRAF-positive metastatic melanoma patients with use of vemurafenib.
Abstract
The incidence of cutaneous melanoma is constantly increasing. The primary treatment in early stage of disease remains surgery. New therapeutic strategies such as immunotherapy or selective BRAF inhibitors — vemurafenib and dabrafenib, have improved outcomes of treatment in the group of patients with stage IV melanoma. In Poland still only vemurafenib is available in routine clinical practice. In this article we present clinical experiences in treating of BRAF-positive metastatic melanoma patients with use of vemurafenib.
About this articleTitle
The use of vemurafenib in BRAF-positive metastatic melanoma patients — selected cases reports
Journal
Nowotwory. Journal of Oncology
Issue
Pages
1-19
Published online
2014-05-14
Page views
807
Article views/downloads
1146
DOI
10.5603/NJO.2014.0016